Title : Placental derived-mesenchymal like stromal adherent cells and their therapeutic potential
Abstract:
Placental-derived mesenchymal-like adherent stromal cells (MLASCs) are proprietary culture expanded, undifferentiated mesenchymal-like adherent stromal cells derived from full term placental tissue that have immuno-modulatory and anti-inflammatory properties. These cells are available in systemic and injectable/local delivery formulations for use in endogenous repair and trophic support. MLASCs are isolated and expanded in a GMP clinical manufacturing facility and have demonstrated high batch-to-batch reproducibility of cell phenotype, growth rate, identity, and purity of final cell product derived from different donors. In vitro studies indicated that MLASCs grow to passage 23 and undergo normal senescence with no evidence of transformation or telomerase expression. MLASCs secrete a wide range of immunomodulatory cytokines (HGF, MCP-1, IL-6, VEGF, PDGF-BB, I-8, etc). In vivo animal studies demonstrated the immunomodulatory effects of MLASCs on innate immune cells (T cells, macrophages, and DC cells). The biodistribution of these cells was established, as well as efficacy in several animal models including Hind Limb Ischemia, Neuritis, Stroke, and Parkinson’s Disease. These cells target specific biological and cellular processes implicated in diseases including Crohn’s disease and diabetic foot ulcers, and diabetic peripheral neuropathy. In clinical studies, MLASCs have demonstrated the capability to support wound closure in patients with DFU and were well tolerated and demonstrated promising clinical response and remission rates in Crohn’s disease patients.
Audience Take Away:
- The presentation will provide key considerations for development of allogeneic off-the shelf cell technologies for various therapeutic applications.
- The characterization studies of MLASC provide a roadmap for development of a scalable allogeneic cell technology for clinical translation.
- The mechanism of action studies discussed in the presentation will provide a de-risking mechanism towards successful clinical translation.
